{"id":"NCT02926950","sponsor":"Lexicon Pharmaceuticals","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11","primaryCompletion":"2019-02-26","completion":"2019-03-22","firstPosted":"2016-10-06","resultsPosted":"2021-05-11","lastUpdate":"2021-05-11"},"enrollment":518,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sotagliflozin (SAR439954)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Sotagliflozin 400 mg + Metformin","type":"EXPERIMENTAL"},{"label":"Placebo + Metformin","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the superiority of Sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control with metformin.\n\nSecondary Objectives:\n\n* To compare Sotagliflozin versus placebo for.\n* Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal.\n* Change from baseline in fasting plasma glucose (FPG).\n* Change from Baseline in systolic blood pressure (SBP) for participants with baseline SBP â‰¥130 millimeter of mercury (mmHg).\n* Change from baseline in SBP for all participants.\n* Change from baseline in body weight.\n* Proportion of participants with HbA1c \\<6.5% and \\<7.0%.\n* To evaluate the safety of Sotagliflozin versus placebo.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Placebo + Metformin","deltaMin":-0.29,"sd":0.079},{"arm":"Sotagliflozin 400 mg + Metformin","deltaMin":-0.77,"sd":0.077}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":20},"locations":{"siteCount":93,"countries":["United States","Canada","Hungary","Slovakia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":259},"commonTop":["Upper respiratory tract infection","Diarrhoea","Vitamin D deficiency","Nasopharyngitis","Urinary tract infection"]}}